Import from '@/components/mdx'

Dayvigo (Lemborexant) Pharmacokinetics: How Your Body Absorbs, Processes, and Clears This Sleep Drug

What Is Lemborexant and How Does It Work?

Lemborexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the brain. Orexins, also called hypocretins, are neuropeptides that keep you awake and alert. By occupying both receptor subtypes, lemborexant dampens the wake-promoting signal without globally suppressing the central nervous system the way older sleep aids such as benzodiazepines or Z-drugs do.

The Orexin System and Why It Matters for Women

The orexin system does not operate in isolation. Estrogen and progesterone receptors are expressed in orexin-producing neurons in the lateral hypothalamus. Animal data suggest that estradiol modulates orexin tone, which may partly explain why insomnia worsens during perimenopause as estrogen falls. Progesterone has GABAergic properties of its own, so the postpartum or late-luteal progesterone drop can also fragment sleep through overlapping but distinct pathways.

This hormonal context means the orexin system is not sex-neutral. The pharmacokinetic differences between women and men described below probably interact with fluctuating hormonal status across the menstrual cycle and across life stages, though direct cycle-phase PK data for lemborexant are not yet published. That is an honest evidence gap worth naming.

Dual vs. Single Orexin Blockade

Earlier DORAs such as suvorexant (Belsomra) also hit both receptors. Lemborexant binds with higher affinity and shows a somewhat more balanced OX1R/OX2R profile, which its developers proposed as a reason for the cleaner next-morning residual profile seen in SUNRISE-1. Whether that mechanistic nuance translates to a clinically meaningful difference for women specifically has not been tested head-to-head in female-only cohorts.

Absorption: Getting Into Your Bloodstream

Lemborexant is absorbed from the gastrointestinal tract and reaches maximum plasma concentration (Cmax) in approximately 1 to 3 hours after an oral dose. Absolute bioavailability in humans has not been formally published in open literature as of this writing, but the drug is well enough absorbed to achieve therapeutic receptor occupancy at 5 mg and 10 mg doses.

Food Effects

A high-fat meal delays Tmax by about 2 hours and reduces Cmax by roughly 35%, though the FDA label notes this delay may impair sleep onset. The clinical recommendation is to take lemborexant within 30 minutes of bedtime and not right after a heavy meal. For women who eat late because of household or caregiving demands, this timing instruction is worth emphasizing explicitly.

Does the Menstrual Cycle Affect Absorption?

Gastric motility changes across the menstrual cycle. Progesterone slows gut motility in the luteal phase, which could theoretically extend Tmax. No published PK study has measured lemborexant absorption across cycle phases in premenopausal women. That gap exists for most sleep drugs, and lemborexant is no exception.

Distribution: Where the Drug Goes After Absorption

Once absorbed, lemborexant distributes widely. It is approximately 94% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The high protein binding means only a small free fraction is pharmacologically active at any given moment.

Volume of Distribution and Central Nervous System Penetration

The apparent volume of distribution is large, consistent with extensive tissue distribution and central nervous system penetration. A drug targeting orexin receptors in the hypothalamus must cross the blood-brain barrier efficiently, and the lipophilic character of lemborexant supports that. The precise Vd estimate from the population PK model is approximately 87 liters, though this figure varies by source and should be interpreted as an order-of-magnitude estimate.

Sex Differences in Distribution

Women generally have a higher percentage of body fat and lower lean body mass relative to men at similar total body weight. Because lemborexant is lipophilic, its distribution into adipose tissue may differ by sex. The FDA review documents note that women show higher area under the curve (AUC) and higher Cmax than men after the same nominal dose. A portion of that difference is likely distributional, in addition to metabolic differences discussed below.

Metabolism: How Your Liver Breaks Down Lemborexant

This is where sex differences become most clinically meaningful. Lemborexant is metabolized almost entirely by CYP3A4 and CYP3A5 in the liver and, to a lesser degree, the gut wall. Three metabolites have been identified: M4, M9, and M10. M4 retains pharmacological activity at OX1R and OX2R, meaning the drug's effect does not stop the moment the parent compound is cleared.

CYP3A and Hormonal Interactions

CYP3A4 activity is not static. Estrogen and progesterone both modulate CYP3A4 expression, and published pharmacokinetic work across the menstrual cycle shows that CYP3A4 activity increases in the luteal phase relative to the follicular phase. If that pattern applies to lemborexant, women might clear the drug faster mid-cycle and more slowly in the late luteal phase, with potential consequences for both therapeutic effect and next-morning residual sedation.

A practical framework for thinking about this: cycle-phase CYP3A4 variation probably produces a 10 to 20% swing in lemborexant clearance within a premenopausal woman across her cycle, based on the magnitude of CYP3A modulation documented with other CYP3A substrates such as midazolam and nifedipine. No direct lemborexant cycle-phase data exist, so this remains an extrapolation, not confirmed evidence. Clinicians counseling premenopausal women on this drug should be aware that premenstrual nights, when both progesterone and CYP3A4 activity are dropping, may carry slightly higher drug exposure.

CYP3A Inhibitors and Inducers

Because lemborexant is so dependent on CYP3A, drug interactions are a real clinical concern. Strong CYP3A inhibitors, including fluconazole, clarithromycin, and ritonavir, can substantially raise lemborexant plasma concentrations and are either contraindicated or require significant dose reduction. Fluconazole is among the most commonly prescribed drugs in women, used for vaginal candidiasis, so this interaction is not theoretical.

Strong CYP3A inducers such as rifampin and carbamazepine can reduce lemborexant exposure to ineffective levels. The label advises against combining lemborexant with strong or moderate CYP3A inducers. Women on enzyme-inducing antiseizure medications, which are sometimes prescribed for neuropathic pain or migraine prevention, should have that interaction checked before starting lemborexant.

Hormonal Contraceptives and CYP3A

Combined oral contraceptives (COCs) contain ethinyl estradiol and a progestin, both of which are CYP3A substrates. COCs are not listed as contraindicated with lemborexant, and no dedicated drug interaction study between COCs and lemborexant appears in the published literature. Given the shared CYP3A pathway, coadministration could, in theory, modestly alter exposures in both directions. Women on COCs who are prescribed lemborexant should be aware of this unstudied interaction.

Excretion and Half-Life: How Long the Drug Stays in Your System

Lemborexant and its metabolites are excreted primarily in feces (approximately 57%) with renal excretion accounting for about 29% of the dose. The terminal elimination half-life of the parent compound is approximately 17 to 19 hours in healthy adults.

Why Half-Life Matters for Next-Morning Function

A half-life of 17 to 19 hours means that if you take lemborexant at 11 PM, a meaningful fraction of the drug remains at 8 AM. This is the pharmacokinetic basis for the next-morning driving impairment signals that appeared in SUNRISE-1, particularly at the 10 mg dose. The FDA label includes a warning about next-morning psychomotor impairment and advises women not to drive after taking the 10 mg dose until they know how the drug affects them.

Women Have Longer Effective Half-Lives

Population PK modeling from the FDA review indicates that women have approximately 22% higher AUC than men after the same dose, with correspondingly higher Cmax and a longer apparent half-life. This is not a trivial difference. It means the 10 mg dose in a woman is pharmacokinetically more like a 12 mg dose in a man. The approved starting dose of 5 mg, with dose escalation to 10 mg only if needed, partly acknowledges this sex difference, though the label does not provide a separate female dosing algorithm.

Renal and Hepatic Impairment

Mild or moderate hepatic impairment prolongs the half-life further. The label recommends a maximum dose of 5 mg in patients with moderate hepatic impairment and advises avoiding lemborexant in severe hepatic impairment. Renal impairment does not substantially alter parent compound PK, though metabolite accumulation has not been fully characterized in severe kidney disease.

Older age, particularly relevant for postmenopausal women, is associated with reduced CYP3A4 activity and lower albumin, both of which increase free drug exposure. The label notes that AUC was approximately 20% higher in elderly subjects, compounding the sex difference in older women.

Sex-Specific Pharmacokinetics: The Evidence Summary

Women are not studied enough in dedicated PK trials. The lemborexant data come largely from population PK analyses pooled across mixed-sex trial populations, which are less precise than dedicated female-cohort studies. Here is an honest accounting of what is known and what is extrapolated:

| Parameter | Women vs. Men | Data Quality | |---|---|---| | AUC | ~22% higher in women | Population PK model | | Cmax | Higher in women | Population PK model | | Half-life | Longer in women | Population PK model | | Cycle-phase variation | Unknown | No direct data | | Postmenopausal vs. Premenopausal | Unknown | No direct data | | COC interaction | Unknown | No dedicated study |

The honest clinical takeaway is that the female-specific PK advantage of a lower starting dose is supported by population modeling, not by a dedicated women's trial. Clinicians should treat the 5 mg starting dose as especially important for women, and should be more cautious about escalation to 10 mg in older or perimenopausal patients.

Life-Stage Guide: Who Needs to Think Most Carefully About These PK Differences

Reproductive Years (Ages 18 to 45)

Women in their reproductive years taking lemborexant should be aware of the CYP3A interaction with fluconazole, which is extremely common in this age group. A single 150 mg fluconazole dose for vaginal candidiasis can inhibit CYP3A for 3 to 5 days, potentially doubling lemborexant exposure during that window. Avoid or skip lemborexant doses during fluconazole courses until more precise interaction data are published.

Perimenopause (Typically Ages 45 to 55)

Perimenopause carries the highest insomnia burden of any female life stage. Up to 60% of perimenopausal women report clinically significant sleep disturbance. Hot flashes fragment sleep architecture independently of the orexin system, so lemborexant addresses one pathway while vasomotor symptoms continue through another. The PK implication for this group is that declining estrogen may reduce CYP3A4 induction, modestly increasing lemborexant exposure relative to the premenopausal state. No direct data confirm this, and it is an extrapolation from estrogen's known CYP3A effects.

Postmenopause (Ages 55 and Older)

Older postmenopausal women have lower CYP3A4 activity from age-related hepatic decline and reduced albumin, meaning both higher free drug exposure and slower clearance. The 5 mg dose is the right starting point. Escalation to 10 mg should be reserved for women who show no next-morning grogginess, no fall risk, and no CNS-depressant polypharmacy.

Trying to Conceive

Lemborexant has no established safe use in women trying to conceive. Given the lack of human reproductive safety data, use the lowest effective dose for the shortest time, and stop the drug once pregnancy is confirmed. Discuss contraception use with your prescriber if you are sexually active and not currently trying to conceive.

Pregnancy and Lactation Safety

Lemborexant is not approved for use during pregnancy. The FDA label carries no established safety data in pregnant women.

Animal studies used doses generating AUC exposures approximately 12 to 61 times the maximum human dose and did not identify teratogenic effects in rats and rabbits at lower multiples. At higher multiples, fetal developmental findings were noted. The relevance to human pregnancy at clinical doses is unknown, and the absence of teratogenicity in animal studies does not mean the drug is safe in human pregnancy.

What to Do If You Become Pregnant on Lemborexant

Stop the drug and contact your prescriber immediately. No data exist on fetal outcomes after first-trimester exposure in humans. Enroll in the Eisai pregnancy registry (referenced in the label) if you are willing, as population-level case data from registries are currently the only way to generate human safety signals for this drug in pregnancy.

Lactation

Lemborexant transfer into human breast milk has not been studied. Given the drug's lipophilicity and large volume of distribution, passive transfer into milk is plausible. The developmental and health effects on the breastfeeding infant are unknown. Avoid lemborexant while breastfeeding. If sleep in the postpartum period is severely new, discuss safer alternatives with your provider, including cognitive behavioral therapy for insomnia (CBT-I), which has evidence in postpartum women and carries no exposure risk to the infant.

Contraception Requirement

No specific contraception mandate appears in the lemborexant label, unlike some medications with confirmed teratogenic risk. However, given the complete absence of human pregnancy safety data, women who are sexually active and not planning pregnancy should use reliable contraception while on lemborexant as a precautionary measure.

Drug Interactions Most Relevant to Women

Beyond CYP3A inhibitors and inducers already discussed, several interactions disproportionately affect women's prescribing patterns:

• Antidepressants (SSRIs, SNRIs): Many women take these for depression, anxiety, or perimenopausal mood symptoms. Most SSRIs are not strong CYP3A modulators, but fluvoxamine is a potent CYP3A inhibitor and would substantially raise lemborexant levels. Avoid the combination.
• Benzodiazepines and Z-drugs: Additive CNS depression. Given that women are already prescribed these drugs at higher rates than men, the combination is clinically common and should be avoided.
• Opioids: CNS and respiratory depression risk is additive. Women with chronic pain on opioids who are also struggling with insomnia need a careful conversation about whether lemborexant is appropriate.
• Alcohol: Even moderate alcohol consumption prolongs the sedative effect and increases fall risk through pharmacodynamic additivity. The label advises avoiding alcohol, but perimenopausal and postmenopausal women who use alcohol to self-manage sleep or mood should hear this instruction clearly.

Who This Drug Is Right For (and Who Should Be Cautious)

More Likely to Benefit

• Postmenopausal women with chronic insomnia who have tried CBT-I or found it insufficient.
• Perimenopausal women whose insomnia is sleep-maintenance dominant (frequent nighttime awakenings) rather than purely onset-related, which aligns with orexin dysregulation more than purely vasomotor causes.
• Women who cannot tolerate next-day sedation from longer-acting benzodiazepine receptor agonists.

Use With Extra Caution

• Women older than 65, because of the compounded sex-plus-age PK effect.
• Women on any moderate or strong CYP3A inhibitor or inducer.
• Women with moderate hepatic impairment (maximum 5 mg dose applies).
• Women who drive professionally or have occupations requiring psychomotor precision in the morning.
• Women who are pregnant, breastfeeding, or actively trying to conceive.

SUNRISE-1 and What the Trial Data Tell Us

SUNRISE-1 was a randomized, double-blind, placebo-controlled and active-controlled Phase 3 trial published in JAMA Network Open in 2019. It enrolled 291 adults with insomnia disorder and compared lemborexant 5 mg, lemborexant 10 mg, and zolpidem extended-release 6.25 mg over one month.

The trial found that both lemborexant doses outperformed placebo on subjective sleep onset latency and wake after sleep onset. Compared to zolpidem ER, lemborexant showed statistically significantly better next-morning residual effects on measures of sleepiness and balance (postural stability), which is directly relevant to fall risk in older women.

SUNRISE-1 enrolled approximately 65% women, which is higher than many sleep drug trials and reflects the real-world sex distribution of insomnia. However, the trial did not publish sex-stratified efficacy or PK results as a primary analysis. The conclusion that lemborexant works in women is drawn from a predominantly female sample, not from a pre-specified female subgroup analysis. That distinction matters for interpreting effect size certainty.

The 10 mg dose showed greater next-morning impairment than the 5 mg dose on driving simulation tests in separate studies conducted by Eisai, which formed the basis for the FDA's next-morning driving advisory that applies specifically and with extra weight to women, given their higher AUC at the same dose.

Practical Dosing Takeaways for Women

Start at 5 mg. That is the right first dose for most women, and for women older than 65, it should remain the target dose unless there is a compelling reason to escalate. Take it within 30 minutes of going to bed, not right after a large meal. Allow at least 7 hours before planned awakening, and for the 10 mg dose, consider 8 hours if morning precision tasks are required.

If you take fluconazole for a yeast infection, skip your lemborexant dose for the duration of the course and for 48 hours after the last fluconazole dose, then restart at the lowest effective dose. Confirm this plan with your prescriber in advance, since fluconazole courses are frequent enough in reproductive-age women that this scenario will arise.

The long half-life of 17 to 19 hours, extended further in women, means that missed-dose anxiety is not clinically meaningful. Skipping a night or two does not require a restart protocol. It also means that drug accumulation over several nights of use is real: steady-state concentrations are higher than single-dose levels, and next-morning sedation may become more noticeable in the first week of use before your body equilibrates.